MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

Search

CytomX Therapeutics Inc

Cerrado

SectorSanidad

5.41 27.29

Resumen

Variación precio

24h

Actual

Mínimo

5.36

Máximo

5.55

Métricas clave

By Trading Economics

Ingresos

-14M

-14M

Ventas

-13M

6M

P/B

Media del Sector

14.467

90.831

Margen de beneficios

-238.621

Empleados

119

EBITDA

-13M

-14M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+31.73% upside

Dividendos

By Dow Jones

Próximas Ganancias

5 mar 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

87M

735M

Apertura anterior

-21.88

Cierre anterior

5.41

Noticias sobre sentimiento de mercado

By Acuity

22%

78%

28 / 361 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Strong Bullish Evidence

CytomX Therapeutics Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

16 ene 2026, 23:29 UTC

Acciones populares

Stocks to Watch: Atossa Therapeutics, Union Pacific

18 ene 2026, 23:57 UTC

Adquisiciones, fusiones, absorciones

Elliott: Standalone Plan Offers Clear Path to Valuation of More Than Y40,000 a Share by 2028

18 ene 2026, 23:57 UTC

Adquisiciones, fusiones, absorciones

Elliott: Opposing Toyota Fudosan's Revised Tender Offer for Toyota Industries

18 ene 2026, 23:55 UTC

Charlas de Mercado

Oil Falls as Middle East Tensions Continue to Fade -- Market Talk

18 ene 2026, 23:40 UTC

Charlas de Mercado

Precious Metals Climb After Trump Threatens Europe With Tariffs Over Greenland -- Market Talk

18 ene 2026, 22:29 UTC

Charlas de Mercado

Miners Seen Extending Rally as Generalist Investors Warm to Sector -- Market Talk

18 ene 2026, 21:03 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

18 ene 2026, 21:03 UTC

Charlas de Mercado

More Australian Voters Switch Away From Major Parties -- Market Talk

18 ene 2026, 19:46 UTC

Charlas de Mercado

FX Markets Taking Latest Trump Tariff Threat Calmly -- Market Talk

17 ene 2026, 15:06 UTC

Adquisiciones, fusiones, absorciones

Trump Purchased Netflix, Warner Bonds in Days After Deal Announcement -- Update

17 ene 2026, 03:10 UTC

Adquisiciones, fusiones, absorciones

Trump Purchased Netflix, Warner Bonds In Days After Deal Announcement -- WSJ

16 ene 2026, 22:48 UTC

Adquisiciones, fusiones, absorciones

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- 2nd Update

16 ene 2026, 22:43 UTC

Adquisiciones, fusiones, absorciones

Union Pacific: Additional Information Requested to Be Provided to Surface Transportation Board

16 ene 2026, 22:22 UTC

Adquisiciones, fusiones, absorciones

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- Update

16 ene 2026, 21:50 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Tech, Media & Telecom Roundup: Market Talk

16 ene 2026, 21:50 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Auto & Transport Roundup: Market Talk

16 ene 2026, 21:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

16 ene 2026, 21:50 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

16 ene 2026, 21:48 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Union Pacific, Norfolk Southern Market Share Ruled as Faulty -- Market Talk

16 ene 2026, 21:41 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Union Pacific, Norfolk Southern Deal Rejection Leaves Questions -- Market Talk

16 ene 2026, 21:38 UTC

Adquisiciones, fusiones, absorciones

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- WSJ

16 ene 2026, 21:30 UTC

Adquisiciones, fusiones, absorciones

STB: Union Pacific, Norfolk Southern Application Doesn't Include 'Projected Market Shares' as Required

16 ene 2026, 21:30 UTC

Adquisiciones, fusiones, absorciones

STB: Union Pacific, Norfolk Southern Application Doesn't Include Certain Schedules, Documents Expressly Made Part of Merger Agreement

16 ene 2026, 21:30 UTC

Adquisiciones, fusiones, absorciones

STB: Union Pacific, Norfolk Southern Application Doesn't Contain Certain Information Required by Regulations

16 ene 2026, 21:30 UTC

Adquisiciones, fusiones, absorciones

STB: Application Rejected Without Prejudice to Union Pacific, Norfolk Southern Refiling Revised Application Remedying Deficiencies

16 ene 2026, 21:30 UTC

Adquisiciones, fusiones, absorciones

Surface Transportation Board: Union Pacific, Norfolk Southern Major Merger Application Filed Dec. 19 Incomplete

16 ene 2026, 20:44 UTC

Ganancias

5 Takeaways From This Season's Wealth Management Earnings -- Barrons.com

16 ene 2026, 20:42 UTC

Charlas de Mercado

Oil Futures Post Fourth Straight Weekly Gain -- Market Talk

16 ene 2026, 20:28 UTC

Charlas de Mercado

U.S. Natural Gas Slips Ahead of Long Weekend -- Market Talk

16 ene 2026, 19:12 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Netflix Could Comment on Structure of Warner Bid During 4Q Results -- Market Talk

Comparación entre iguales

Cambio de precio

CytomX Therapeutics Inc previsión

Precio Objetivo

By TipRanks

31.73% repunte

Estimación a 12 Meses

Media 7.1 USD  31.73%

Máximo 10 USD

Mínimo 6 USD

De acuerdo con 6 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para CytomX Therapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

6 ratings

5

Comprar

1

Mantener

0

Vender

Puntuación técnica

By Trading Central

0.7658 / N/ASoporte y Resistencia

Corto Plazo

Strong Bullish Evidence

Medio plazo

Very Strong Bullish Evidence

Largo Plazo

Weak Bullish Evidence

Sentimiento

By Acuity

28 / 361 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura alcista notoria

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de CytomX Therapeutics Inc

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab). CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.